Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1

Raymond Hickey, Shennen A. Mao, Jaime Glorioso, Faysal Elgilani, Bruce Amiot, Harvey Chen, Piero Rinaldo, Ronald J Marler, Huailei Jiang, Timothy R DeGrado, Lukkana Suksanpaisan, Michael K. O'Connor, Brittany L. Freeman, Samar C Ibrahim, Kah-Whye Peng, Cary O. Harding, Chak Sum Ho, Markus Grompe, Yasuhiro H Ikeda, Joseph B. LillegardStephen J Russell, Scott Nyberg

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We tested the hypothesis that ex vivo hepatocyte gene therapy can correct the metabolic disorder in fumarylacetoacetate hydrolase-deficient (Fah-/-) pigs, a large animalmodel of hereditary tyrosinemia type 1 (HT1). Recipient Fah-/- pigs underwent partial liver resection and hepatocyte isolation by collagenase digestion. Hepatocytes were transduced with one or both of the lentiviral vectors expressing the therapeutic Fah and the reporter sodium-iodide symporter (Nis) genes under control of the thyroxine-binding globulin promoter. Pigs received autologous transplants of hepatocytes by portal vein infusion. After transplantation, the protective drug 2-(2-nitro-4-trifluoromethylbenzyol)- 1,3 cyclohexanedione (NTBC) was withheld from recipient pigs to provide a selective advantage for expansion of corrected FAH+ cells. Proliferation of transplanted cells, assessed by both immunohistochemistry and noninvasive positron emission tomography imaging of NIS-labeled cells, demonstrated near-complete liver repopulation by gene-corrected cells. Tyrosine and succinylacetone levels improved to within normal range, demonstrating complete correction of tyrosine metabolism. In addition, repopulation of the Fah-/- liver with transplanted cells inhibited the onset of severe fibrosis, a characteristic of nontransplanted Fah-/- pigs. This study demonstrates correction of disease in a pig model of metabolic liver disease by ex vivo gene therapy. To date, ex vivo gene therapy has only been successful in small animal models. We conclude that further exploration of ex vivo hepatocyte genetic correction is warranted for clinical use.

Original languageEnglish (US)
Article number349ra99
JournalScience Translational Medicine
Volume8
Issue number349
DOIs
StatePublished - Jul 27 2016

Fingerprint

Tyrosinemias
Genetic Therapy
Swine
Hepatocytes
Liver
Tyrosine
Thyroxine-Binding Globulin
Protective Agents
Metabolic Diseases
Autografts
Collagenases
Portal Vein
Positron-Emission Tomography
Genes
Liver Diseases
Digestion
Reference Values
Fibrosis
Animal Models
Transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. / Hickey, Raymond; Mao, Shennen A.; Glorioso, Jaime; Elgilani, Faysal; Amiot, Bruce; Chen, Harvey; Rinaldo, Piero; Marler, Ronald J; Jiang, Huailei; DeGrado, Timothy R; Suksanpaisan, Lukkana; O'Connor, Michael K.; Freeman, Brittany L.; Ibrahim, Samar C; Peng, Kah-Whye; Harding, Cary O.; Ho, Chak Sum; Grompe, Markus; Ikeda, Yasuhiro H; Lillegard, Joseph B.; Russell, Stephen J; Nyberg, Scott.

In: Science Translational Medicine, Vol. 8, No. 349, 349ra99, 27.07.2016.

Research output: Contribution to journalArticle

Hickey, R, Mao, SA, Glorioso, J, Elgilani, F, Amiot, B, Chen, H, Rinaldo, P, Marler, RJ, Jiang, H, DeGrado, TR, Suksanpaisan, L, O'Connor, MK, Freeman, BL, Ibrahim, SC, Peng, K-W, Harding, CO, Ho, CS, Grompe, M, Ikeda, YH, Lillegard, JB, Russell, SJ & Nyberg, S 2016, 'Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1', Science Translational Medicine, vol. 8, no. 349, 349ra99. https://doi.org/10.1126/scitranslmed.aaf3838
Hickey, Raymond ; Mao, Shennen A. ; Glorioso, Jaime ; Elgilani, Faysal ; Amiot, Bruce ; Chen, Harvey ; Rinaldo, Piero ; Marler, Ronald J ; Jiang, Huailei ; DeGrado, Timothy R ; Suksanpaisan, Lukkana ; O'Connor, Michael K. ; Freeman, Brittany L. ; Ibrahim, Samar C ; Peng, Kah-Whye ; Harding, Cary O. ; Ho, Chak Sum ; Grompe, Markus ; Ikeda, Yasuhiro H ; Lillegard, Joseph B. ; Russell, Stephen J ; Nyberg, Scott. / Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. In: Science Translational Medicine. 2016 ; Vol. 8, No. 349.
@article{2f8ee1fc967743cebcd5f18a90e063d0,
title = "Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1",
abstract = "We tested the hypothesis that ex vivo hepatocyte gene therapy can correct the metabolic disorder in fumarylacetoacetate hydrolase-deficient (Fah-/-) pigs, a large animalmodel of hereditary tyrosinemia type 1 (HT1). Recipient Fah-/- pigs underwent partial liver resection and hepatocyte isolation by collagenase digestion. Hepatocytes were transduced with one or both of the lentiviral vectors expressing the therapeutic Fah and the reporter sodium-iodide symporter (Nis) genes under control of the thyroxine-binding globulin promoter. Pigs received autologous transplants of hepatocytes by portal vein infusion. After transplantation, the protective drug 2-(2-nitro-4-trifluoromethylbenzyol)- 1,3 cyclohexanedione (NTBC) was withheld from recipient pigs to provide a selective advantage for expansion of corrected FAH+ cells. Proliferation of transplanted cells, assessed by both immunohistochemistry and noninvasive positron emission tomography imaging of NIS-labeled cells, demonstrated near-complete liver repopulation by gene-corrected cells. Tyrosine and succinylacetone levels improved to within normal range, demonstrating complete correction of tyrosine metabolism. In addition, repopulation of the Fah-/- liver with transplanted cells inhibited the onset of severe fibrosis, a characteristic of nontransplanted Fah-/- pigs. This study demonstrates correction of disease in a pig model of metabolic liver disease by ex vivo gene therapy. To date, ex vivo gene therapy has only been successful in small animal models. We conclude that further exploration of ex vivo hepatocyte genetic correction is warranted for clinical use.",
author = "Raymond Hickey and Mao, {Shennen A.} and Jaime Glorioso and Faysal Elgilani and Bruce Amiot and Harvey Chen and Piero Rinaldo and Marler, {Ronald J} and Huailei Jiang and DeGrado, {Timothy R} and Lukkana Suksanpaisan and O'Connor, {Michael K.} and Freeman, {Brittany L.} and Ibrahim, {Samar C} and Kah-Whye Peng and Harding, {Cary O.} and Ho, {Chak Sum} and Markus Grompe and Ikeda, {Yasuhiro H} and Lillegard, {Joseph B.} and Russell, {Stephen J} and Scott Nyberg",
year = "2016",
month = "7",
day = "27",
doi = "10.1126/scitranslmed.aaf3838",
language = "English (US)",
volume = "8",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "349",

}

TY - JOUR

T1 - Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1

AU - Hickey, Raymond

AU - Mao, Shennen A.

AU - Glorioso, Jaime

AU - Elgilani, Faysal

AU - Amiot, Bruce

AU - Chen, Harvey

AU - Rinaldo, Piero

AU - Marler, Ronald J

AU - Jiang, Huailei

AU - DeGrado, Timothy R

AU - Suksanpaisan, Lukkana

AU - O'Connor, Michael K.

AU - Freeman, Brittany L.

AU - Ibrahim, Samar C

AU - Peng, Kah-Whye

AU - Harding, Cary O.

AU - Ho, Chak Sum

AU - Grompe, Markus

AU - Ikeda, Yasuhiro H

AU - Lillegard, Joseph B.

AU - Russell, Stephen J

AU - Nyberg, Scott

PY - 2016/7/27

Y1 - 2016/7/27

N2 - We tested the hypothesis that ex vivo hepatocyte gene therapy can correct the metabolic disorder in fumarylacetoacetate hydrolase-deficient (Fah-/-) pigs, a large animalmodel of hereditary tyrosinemia type 1 (HT1). Recipient Fah-/- pigs underwent partial liver resection and hepatocyte isolation by collagenase digestion. Hepatocytes were transduced with one or both of the lentiviral vectors expressing the therapeutic Fah and the reporter sodium-iodide symporter (Nis) genes under control of the thyroxine-binding globulin promoter. Pigs received autologous transplants of hepatocytes by portal vein infusion. After transplantation, the protective drug 2-(2-nitro-4-trifluoromethylbenzyol)- 1,3 cyclohexanedione (NTBC) was withheld from recipient pigs to provide a selective advantage for expansion of corrected FAH+ cells. Proliferation of transplanted cells, assessed by both immunohistochemistry and noninvasive positron emission tomography imaging of NIS-labeled cells, demonstrated near-complete liver repopulation by gene-corrected cells. Tyrosine and succinylacetone levels improved to within normal range, demonstrating complete correction of tyrosine metabolism. In addition, repopulation of the Fah-/- liver with transplanted cells inhibited the onset of severe fibrosis, a characteristic of nontransplanted Fah-/- pigs. This study demonstrates correction of disease in a pig model of metabolic liver disease by ex vivo gene therapy. To date, ex vivo gene therapy has only been successful in small animal models. We conclude that further exploration of ex vivo hepatocyte genetic correction is warranted for clinical use.

AB - We tested the hypothesis that ex vivo hepatocyte gene therapy can correct the metabolic disorder in fumarylacetoacetate hydrolase-deficient (Fah-/-) pigs, a large animalmodel of hereditary tyrosinemia type 1 (HT1). Recipient Fah-/- pigs underwent partial liver resection and hepatocyte isolation by collagenase digestion. Hepatocytes were transduced with one or both of the lentiviral vectors expressing the therapeutic Fah and the reporter sodium-iodide symporter (Nis) genes under control of the thyroxine-binding globulin promoter. Pigs received autologous transplants of hepatocytes by portal vein infusion. After transplantation, the protective drug 2-(2-nitro-4-trifluoromethylbenzyol)- 1,3 cyclohexanedione (NTBC) was withheld from recipient pigs to provide a selective advantage for expansion of corrected FAH+ cells. Proliferation of transplanted cells, assessed by both immunohistochemistry and noninvasive positron emission tomography imaging of NIS-labeled cells, demonstrated near-complete liver repopulation by gene-corrected cells. Tyrosine and succinylacetone levels improved to within normal range, demonstrating complete correction of tyrosine metabolism. In addition, repopulation of the Fah-/- liver with transplanted cells inhibited the onset of severe fibrosis, a characteristic of nontransplanted Fah-/- pigs. This study demonstrates correction of disease in a pig model of metabolic liver disease by ex vivo gene therapy. To date, ex vivo gene therapy has only been successful in small animal models. We conclude that further exploration of ex vivo hepatocyte genetic correction is warranted for clinical use.

UR - http://www.scopus.com/inward/record.url?scp=84980025204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980025204&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aaf3838

DO - 10.1126/scitranslmed.aaf3838

M3 - Article

C2 - 27464750

AN - SCOPUS:84980025204

VL - 8

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 349

M1 - 349ra99

ER -